-
Hengrui Medicine Gets NMPA Green Light for Phase Ib/II Study of SHR-A1921 Combo in Advanced Solid Tumors
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate an open, multi-center Phase Ib/II clinical study for its injectable pipeline candidate SHR-A1921. This investigational treatment is to be used in combination with adebrelimab (SHR-1316) and SHR-8068…
-
Biocytogen Strikes Exclusive Licensing Deal with US-Based Radiance Biopharma for Innovative BsADC
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a leading biopharmaceutical company based in China , has announced the signing of an Exclusive Option and License Agreement with Radiance Biopharma Inc., a specialist in antibody drug conjugates (ADCs) headquartered in Boston, U.S. The agreement provides Radiance with the option to license…
-
MSD Advances Four Oncology Candidates to Late-Stage Trials, Including Partnerships with Kelun-Biotech and Orion
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced significant progress in its oncology pipeline with the advancement of four candidates to late-stage trials that are currently enrolling participants. The first molecule is the LSD1 inhibitor bomedemstat, which is being developed for the treatment of essential thrombocythemia (ET). Nemtabrutinib, a…
-
AstraZeneca Secures Exclusive Rights to Omniose’s Enzyme Platform for Bacterial Vaccine Development
•
AstraZeneca (AZ; NASDAQ: AZN) has secured an exclusive licensing agreement with biotechnology firm Omniose for up to three years, gaining access to Omniose’s enzyme-based bioconjugation platform. This platform will be utilized for the development of vaccines targeting bacterial pathogens, including those that are multidrug-resistant. Omniose’s proprietary enzyme technology enables the…
-
China’s NHSA Aims to Balance Drug Prices with New Monitoring System by March 2024
•
The National Healthcare Security Administration (NHSA) has issued a notification aimed at fostering inter-provincial price fairness, integrity, transparency, and balance for drugs sharing the same generic names and manufacturers. The initiative involves a comprehensive review and inspection of drugs based on four criteria: generic name, manufacturer, dosage form, and specification.…
-
AbbVie Partners with Umoja Biopharma to Develop Next-Generation CAR-T Therapies
•
AbbVie (NYSE: ABBV) has entered into a collaboration agreement with Umoja Biopharma, a US-based company specializing in next-generation in-situ CAR-T cell therapies. Under the partnership, the two companies will develop up to four programs targeting selected cancer therapies chosen by AbbVie. AbbVie has also secured an exclusive option to license…
-
Weigao Blood Purification Aims for USD 190 Million in Shanghai Stock Exchange IPO
•
Shandong Weigao Blood Purification Products Co., Ltd, a dominant player in China’s blood purification sector, has submitted an initial public offering (IPO) application to the Shanghai Stock Exchange (SSE). The exchange has accepted the filing for review, with the company eyeing a substantial capital injection of RMB 1.351 billion (USD…
-
BMS’s Abraxane Approved in China for First-Line Metastatic Pancreatic Cancer Treatment
•
Bristol Myers Squibb (BMS, NYSE: BMY), a leading U.S. pharmaceutical company, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its drug Abraxane (paclitaxel, albumin). This approval is for the first-line treatment of metastatic pancreatic cancer in combination with gemcitabine. Since June 2008,…
